In recent years, PSMA-related imaging agents have rapidly developed, gradually replacing traditional 18F/11C-choline, 18F-FDG and 18F-fluciclovine, dominating the field of PET diagnosis for prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.